Calcium channel blocker in patients with chronic kidney disease

• 資料種別: 記事
• タイトル: Calcium channel blocker in patients with chronic kidney disease
• 著者・編者: Shoko Ohno; Akira Ishii; Motoko Yanagita
• 出版事項: 日本 : Springer Nature
• 出版年月日等: 2021-11-08
• 出版年（W3CDTF）: 2021-11-08
• タイトル（掲載誌）: Clinical and experimental nephrology : official publication of the Japanese Society of Nephrology
• 巻号年月日等（掲載誌）: 26(3)
• 掲載巻: 26(3)
• ISSN（掲載誌）: 1437-7799
• ISSN-L（掲載誌）: 1437-7799
• 本文の言語コード: eng
• DOI: 10.1007/s10157-021-02153-1; https://doi.org/10.1007/s10157-021-02153-1
• 国立国会図書館永続的識別子: info:ndljp/pid/12289733; https://dl.ndl.go.jp/pid/12289733
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• 収集根拠: オンライン資料収集制度
• 受理日（W3CDTF）: 2022-05-23T15:55:37+09:00
• 保存日（W3CDTF）: 2022-05-16
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: https://link.springer.com/article/10.1007/s10157-021-02153-1
• 掲載誌（国立国会図書館永続的識別子）: info:ndljp/pid/12289732; https://dl.ndl.go.jp/pid/12289732
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• 要約等: [Background] Chronic kidney disease (CKD) is involved in a progressive deterioration in renal function over the years and is now a global public health problem. Currently, reducing the number of patients progressing to end-stage renal failure is urgently necessary. Hypertension and CKD interact with each other, and good control of blood pressure (BP) can improve CKD patients’ prognosis. With the current global trend for more strict BP control, the importance of BP management and the need for medication to achieve this strict goal are increasing. Calcium channel blockers (CCBs), which target voltage-dependent calcium channels, are frequently used in combination with renin–angiotensin–aldosterone system inhibitors for CKD patients because of their strong BP-lowering properties and relatively few adverse side effects. Calcium channels have several subtypes, including L, N, T, P/Q, and R, and three types of CCBs, L-type CCBs, L-/T-type CCBs, and L-/N-type CCBs, that are available. Nowadays, the new functions and effects of the CCBs are being elucidated. [Conclusion] We should use different types of CCBs properly depending on their pharmacological effects, such as the strength of antihypertensive effects and the organ protection effects, taking into account the pathophysiology of the patients. In this article, the role and the use of CCBs in CKD patients are reviewed.
• DOI: 10.1007/s10157-021-02153-1; https://doi.org/10.1007/s10157-021-02153-1
• オンライン閲覧公開範囲: インターネット公開
• 著作権情報: © The Author(s) 2021; This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
• 関連情報（URI）: http://hdl.handle.net/2433/278427; http://id.ndl.go.jp/digimeta/12289733; https://dl.ndl.go.jp/pid/12289733; https://link.springer.com/content/pdf/10.1007/s10157-021-02153-1.pdf; https://link.springer.com/article/10.1007/s10157-021-02153-1/fulltext.html; https://search.jamas.or.jp/link/ui/2023068171
• 参照: Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure; https://cir.nii.ac.jp/crid/1050001335835604608; Association between the size of healthcare facilities and the intensity of hypertension therapy: a cross-sectional comparison of prescription data from insurance claims data; https://cir.nii.ac.jp/crid/1050293633442850048; Inhibition of N-type Ca[2+] channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure.; https://cir.nii.ac.jp/crid/1050564285766893056; The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019); https://cir.nii.ac.jp/crid/1360005518347767040; Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes; https://cir.nii.ac.jp/crid/1360011144256943488; Molecular and Functional Diversity of Voltage‐Gated Calcium Channels; https://cir.nii.ac.jp/crid/1360011144597845632; Vasodilatory edema: A common side effect of antihypertensive therapy; https://cir.nii.ac.jp/crid/1360011145388969600; KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease; https://cir.nii.ac.jp/crid/1360013170172749952; Attenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channel; https://cir.nii.ac.jp/crid/1360013170612246656; Effects of Vasopeptidase Inhibition on Renal Function and Tubuloglomerular Feedback in Spontaneously Hypertensive Rats; https://cir.nii.ac.jp/crid/1360013171817994880; Clinical studies on pharmacological treatment of hypertension in Japan; https://cir.nii.ac.jp/crid/1360013173016931840; Investigational calcium channel blockers for the treatment of hypertension; https://cir.nii.ac.jp/crid/1360294646218300544; Efficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-Analysis; https://cir.nii.ac.jp/crid/1360294646535206912; Deficiency of T-type Ca²⁺ channels Ca_v3.1 and Ca_v3.2 has no effect on angiotensin II-induced hypertension but differential effect on plasma aldosterone in mice; https://cir.nii.ac.jp/crid/1360294646954257536; Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection; https://cir.nii.ac.jp/crid/1360564064078892672; Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes; https://cir.nii.ac.jp/crid/1360572092687963904; Functional Importance of L- and P/Q-Type Voltage-Gated Calcium Channels in Human Renal Vasculature; https://cir.nii.ac.jp/crid/1360574093498254848; The N- and L-Type Calcium Channel Blocker Cilnidipine Suppresses Renal Injury in Dahl Rats Fed a High-Sucrose Diet, an Experimental Model of Metabolic Syndrome; https://cir.nii.ac.jp/crid/1360574093699425792; Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats; https://cir.nii.ac.jp/crid/1360574094547688576; Vascular Smooth Muscle Cells Express the α_1ASubunit of a P-/Q-Type Voltage-Dependent Ca²⁺Channel, and It Is Functionally Important in Renal Afferent Arterioles; https://cir.nii.ac.jp/crid/1360574095021216000; Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis; https://cir.nii.ac.jp/crid/1360574096140705536; Characterization of three types of calcium channel in the luminal membrane of the distal nephron; https://cir.nii.ac.jp/crid/1360576121733618560; T-type voltage-gated calcium channels regulate the tone of mouse efferent arterioles; https://cir.nii.ac.jp/crid/1360576122329713792; Mechanistic View of Renal Protective Action of Calcium Channel Blockade; https://cir.nii.ac.jp/crid/1360576122449281792; Preserving renal function in adults with hypertension and diabetes: A consensus approach; https://cir.nii.ac.jp/crid/1360855570554695424; Pedal edema—not all dihydropyridine calcium antagonists are created equal; https://cir.nii.ac.jp/crid/1360857595946391168; New Role of P/Q-type Voltage-gated Calcium Channels; https://cir.nii.ac.jp/crid/1360857597962797184; A new-generation N/L-type calcium channel blocker leads to less activation of the renin–angiotensin system compared with conventional L type calcium channel blocker; https://cir.nii.ac.jp/crid/1361137046266016512; Functional disorders of the sympathetic nervous system in mice lacking the α _1B subunit (Ca _v 2.2) of N-type calcium channels; https://cir.nii.ac.jp/crid/1361137046545652608; Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials; https://cir.nii.ac.jp/crid/1361418520218092928; Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis; https://cir.nii.ac.jp/crid/1361418520694023552; Systemic and glomerular hypertension and progression of chronic renal disease: The dilemma of nephrosclerosis; https://cir.nii.ac.jp/crid/1361699995019533824; A Randomized Trial of Intensive versus Standard Blood-Pressure Control; https://cir.nii.ac.jp/crid/1361981468540408832; The α_1G-subunit of a voltage-dependent Ca²⁺channel is localized in rat distal nephron and collecting duct; https://cir.nii.ac.jp/crid/1361981468615178624; Different Effects of L/N-Type and L-Type Calcium Channel Blockers on the Renin-Angiotensin-Aldosterone System in SHR/Izm; https://cir.nii.ac.jp/crid/1361981470063502464; Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients; https://cir.nii.ac.jp/crid/1361981470204697984; Differential Expression of T- and L-Type Voltage-Dependent Calcium Channels in Renal Resistance Vessels; https://cir.nii.ac.jp/crid/1361981470864207872; 2020 International Society of Hypertension Global Hypertension Practice Guidelines; https://cir.nii.ac.jp/crid/1362262944450356224; Ca²⁺Channel Subtypes and Pharmacology in the Kidney; https://cir.nii.ac.jp/crid/1362262945278550784; Tubular and cellular localization of the cardiac L-type calcium channel in rat kidney; https://cir.nii.ac.jp/crid/1362262945948049024; Renal-Protective Effect of T- and L-Type Calcium Channel Blockers in Hypertensive Patients: An Amlodipine-to-Benidipine Changeover (ABC) Study; https://cir.nii.ac.jp/crid/1362262946020202240; Inhibitory Effect of Efonidipine on Aldosterone Synthesis and Secretion in Human Adrenocarcinoma (H295R) Cells; https://cir.nii.ac.jp/crid/1362544419638059776; Structure and Regulation of Voltage-Gated Ca²⁺ Channels; https://cir.nii.ac.jp/crid/1362825893318176000; Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine; https://cir.nii.ac.jp/crid/1362825895359767296; Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats; https://cir.nii.ac.jp/crid/1363107368489791616; Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014; https://cir.nii.ac.jp/crid/1363107369555060480; T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy; https://cir.nii.ac.jp/crid/1363388843902423552; CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004; https://cir.nii.ac.jp/crid/1363388845224585472; Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria; https://cir.nii.ac.jp/crid/1363670319308430720; Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events; https://cir.nii.ac.jp/crid/1363670321221751808; Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte; https://cir.nii.ac.jp/crid/1363951795041692416; Ca2+ Channel α1B Subunit (CaV 2.2) Knockout Mouse Reveals a Predominant Role of N-Type Channels in the Sympathetic Regulation of the Circulatory System; https://cir.nii.ac.jp/crid/1364233268451260288; Molecular Basis for CA2+ Channel Diversity; https://cir.nii.ac.jp/crid/1364233268600068352; Dominant Role of N-Type Ca ²⁺ Channels in Evoked Release of Norepinephrine from Sympathetic Neurons; https://cir.nii.ac.jp/crid/1364233268700884096; Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy; https://cir.nii.ac.jp/crid/1364233268723197056; Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease; https://cir.nii.ac.jp/crid/1364233269759310464; Discovery and Development of Calcium Channel Blockers; https://cir.nii.ac.jp/crid/1364233270270036352; Nomenclature of Voltage-Gated Calcium Channels; https://cir.nii.ac.jp/crid/1364233270526587904; Cilnidipine Attenuates Renal Nerve Stimulation-Induced Renal Vasoconstriction and Antinatriuresis in Anesthetized Dogs.; https://cir.nii.ac.jp/crid/1390001204287473536; Disparate Effects of Calcium Antagonists on Renal Microcirculation.; https://cir.nii.ac.jp/crid/1390001204719908736; Effects of the T/L-type Calcium Channel Blocker Benidipine on Albuminuria and Plasma Aldosterone Concentration; https://cir.nii.ac.jp/crid/1390001205226593664; Effects of L/N-Type Calcium Channel Antagonist, Cilnidipine on Progressive Renal Injuries in Dahl Salt-Sensitive Rats; https://cir.nii.ac.jp/crid/1390282679601201408; N-type Calcium Channel Inhibition With Cilnidipine Elicits Glomerular Podocyte Protection Independent of Sympathetic Nerve Inhibition; https://cir.nii.ac.jp/crid/1390282680156872960
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: 学術機関リポジトリデータベース; https://irdb.nii.ac.jp; 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org; 科学研究費助成事業データベース; https://kaken.nii.ac.jp/ja
• 書誌ID（NDLBibID）: 12289733; http://id.ndl.go.jp/bib/12289733